

**U. PORTO**



FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO

**MESTRADO INTEGRADO EM MEDICINA**

---

2017/2018

Pedro Miguel Barata de Silva Coelho

**Therapeutical uses of microbiote modulation**

março, 2018

FMUP

Pedro Miguel Barata de Silva Coelho

**Therapeutical uses of microbiote modulation**

**Mestrado Integrado em Medicina**

**Área: Ciências da Saúde**

**Tipologia: Monografia**

**Trabalho efetuado sob a Orientação de:**

**Doutora Raquel Soares**

**Trabalho organizado de acordo com as normas da revista:**

**Journal of International Medical Research**

março, 2018

**FMUP**

Eu Pedro Miguel Barata de Silva Coelho, abaixo assinado, nº mecanográfico 199302085, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 19/03/2018

Assinatura conforme cartão de identificação:

\_\_\_\_\_

NOME

Pedro Miguel Barata de Silva Coelho

NÚMERO DE ESTUDANTE

199302085

E-MAIL

Pedro.barata@gmail.com

DESIGNAÇÃO DA ÁREA DO PROJECTO

Ciências da Saúde

TÍTULO DISSERTAÇÃO/MONOGRAFIA (riscar o que não interessa)

Therapeutical uses of microbiote modulation

ORIENTADOR

Prof. Doutora Raquel Soares

COORDINADOR (se aplicável)

Não aplicável

ASSINALE APENAS UMA DAS OPÇÕES:

É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTES TRABALHOS APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	<input type="checkbox"/>
É AUTORIZADA A REPRODUÇÃO PARCIAL DESTES TRABALHOS (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	<input type="checkbox"/>
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) NÃO É PERMITIDA A REPRODUÇÃO DE QUALQUER PARTE DESTES TRABALHOS.	<input checked="" type="checkbox"/>

Faculdade de Medicina da Universidade do Porto, 19/03/2018

Assinatura conforme cartão de identificação: \_\_\_\_\_



**À Bea.**  
**Aos que sempre acreditaram.**

**Trabalho de acordo com as regras da Revista  
Journal of International Medical Research**

**Trabalho de acordo com as regras da Revista  
Journal of International Medical Research**

## **Therapeutical uses of microbiote modulation**

**Pedro Barata<sup>a,b,\*</sup>, Raquel Soares<sup>b,\*</sup>**

<sup>a</sup> Faculty of Health Sciences, Fernando Pessoa University, Rua Carlos da Maia, 296  
4200-150 Porto, Portugal

<sup>b</sup> Department of Biochemistry (I3S), Faculty of Medicine, University of Porto, Al.  
Prof. Hernâni Monteiro, 4200 – 319 Porto, Portugal

### **Corresponding authors:**

Pedro Barata: [pbarata@ufp.edu.pt](mailto:pbarata@ufp.edu.pt)

Phone: +351 22 507 4630

Fax: +351 22 550 4637

Raquel Soares: [raqsoa@med.up.pt](mailto:raqsoa@med.up.pt)

Phone: +351 22 551 3600

Fax: +351 22 551 3601



## **Abstract**

The human Microbiota consists of the 10-100 trillion symbiotic microbial cells harboured by each person that can therefore be considered as an ecosystem or a “super-organism”. Microbiota is the microbial taxa associated with individuals while Microbiome is defined as the collective genomes of the microbes (bacteria, bacteriophage, fungi, protozoa and viruses) that live inside and on the human body.

The gut Microbiota is increasingly regarded as an ‘invisible organ’ of the human body and considered an important factor for host health, playing a major role in homeostasis. It is by far the most studied of all human ecosystems and arguably the one that most impacts global health status. Recently a lot of investigation has been dedicated to the field of Microbiota/Microbiome namely in what concerns the association between quantitative and qualitative changes in Microbiota/Microbiome and several pathologies.

These pathologies include obesity and cardiovascular diseases, diabetes, central nervous system and degenerative diseases among many others. Various strategies can be used in order to modulate Microbiota alterations including administration of antibiotics, prebiotics and probiotics, nutritional interventions and faecal transplants. Even though these strategies seem promising there is still a great need for more robust studies that can verify their effectiveness and evaluate the real relation between Microbiota changes and diseases reviewed.

**Keywords:** Microbiota, Gut Microbiota, Microbiome, Microbiota Interventions

## 1 – INTRODUCTION

Since Antoine van Leeuwenhoek first observed the microorganisms present in the human mouth in his microscope, in 1676, a lot has evolved in the field of Microbiology.

The late 19th century witnessed the development of bacteria culture techniques, instrumental in microbiological research. In the 1970s, strictly anaerobic culture techniques were developed. Yet, it was only after the advent of PCR and genome sequencing, in the 1980s that the field of Microbiota took off. In fact, the first step of the Human Microbiome Project was the sequencing of intestinal bacteria genome, performed by Steven R. Gill.

The initial phase of that project aimed to characterize the microbial communities from healthy individuals, across several different sites on the human body: nasal passages, oral cavity, skin, gastrointestinal tract, and urogenital tract using 16S rRNA sequencing <sup>1</sup>. This delivered the first characterization of the microbial variety and the understanding of the human body less as an entity and more as an ecosystem.

The continuous research on this field provided the first associations between microbial composition and some pathologies, the first being obesity, identifying organisms with either beneficial or harming properties.

The concept of bacteria that is beneficial for the health was first supported by Elie Metchnikoff, regarding the milk fermentation bacteria, and was later supported by the work of Louis Pasteur. The actual metagenomic era is seeing a great expansion of knowledge, evidenced by the ever increasing number of dedicated publications, and is considered by many as a new age for microbiology.

Microbiota is the microbial taxa associated with individuals. The human Microbiota consists of the 10-100 trillion symbiotic microbial cells harboured by each person <sup>2</sup>.

Microbiome is defined as the collective genomes of the microbes (bacteria, bacteriophage, fungi, protozoa and viruses) that live inside and on the human body.

Dysbiosis is the condition of having imbalances in the microbial communities either in or on the body and its pathological relevance is increasing consistently. Of all the human Microbiome ecosystems, the gut is by far the most diverse and probably the most influential on the global health status of an individual. Also, due to its importance and to study feasibility, it is the most thoroughly studied and that whose impact in pathophysiology is better understood. This review aims to characterize the changes in Microbiota and Microbiome occurring in several pathologies as well as to describe therapeutic interventions that aim to increase health through gut Microbiota modulation.

## 2 - GUT MICROBIOME

The gut Microbiota is increasingly regarded as an 'invisible organ' of the human body and considered an important factor for host health <sup>3</sup>, playing a major role in homeostasis. It is by far the most studied of all human ecosystems and arguably the one that most impacts global health status. Mainly composed of bacteria (but also of other eukaryotes, archae, virus and phages), it concentrates mostly in the colon.

The bacterial composition of the gut Microbiota changes along the GI length mainly due to host factors – pH, digestive enzymes, and immune system –, but also due to external factors – nutrients and environmental factors, and even microbial competition and synergies <sup>4</sup>.

Over 30 bacterial phyla have been identified in the bacterial Microbiota with seven phyla accounting for its majority: *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, *Cyanobacteria*, *Fusobacteria*, *Proteobacteria* and *Verrucomicrobia* <sup>5</sup>. The first two are by far the most representative of the gut Microbiota.

The gut Microbiota is established in early childhood and remains relatively stable throughout. Its composition is strongly influenced by factors like mode of birth, diet, diseases and medication <sup>6</sup>. Posterior imbalances or dysbiosis are associated with several pathologies and with the global quality of health of the individual.

### 2.1 - GUT MICROBIOME AND CARDIOVASCULAR DISEASE

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels that are currently the first cause of death worldwide. According to the World Health Organization (WHO), an estimated 17.7 million people died from CVDs in 2015, representing 31% of all global deaths <sup>7</sup>. Such numbers are expected to increase due to the marked incidence, prevalence and severity of the associated risk factors.

Gut dysbiosis is associated with several pathologies that are a cause of or a consequence of cardiovascular disease, namely atherosclerosis, hypertension, heart failure, obesity, type 2 diabetes mellitus, chronic kidney disease and myocardial infarction. The ratio *Firmicutes*-to-*Bacteroides* is the most studied parameter and the one that shows the greater association with different cardiovascular diseases. Additionally, the metabolic potential of gut Microbiota has been identified as a contributing factor in the development of diseases <sup>8</sup>. Gut Microbiota-host interactions occur through many pathways, including trimethylamine-N-oxide and the short-chain fatty acids acetate, propionate and butyrate <sup>9</sup>.

It is known that bacterial composition is affected by many parameters like lifestyle factors, including diet and concomitant diseases. However, the real impact of dysbiosis and its role as a biomarker or as a therapeutic target is yet to be fully disclosed.

#### 2.1.1. GUT MICROBIOME AND HIGH BLOOD PRESSURE

Elevated blood pressure is defined as 120 to 129 mm Hg systolic with a diastolic pressure below 80 mm Hg; Stage 1 hypertension as 130 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic; and Stage 2 hypertension as 140/90 mm Hg or higher <sup>10</sup>.

High blood pressure is a complex and multifactorial condition influenced by a combination of genetic and environmental factors, including physical inactivity, obesity, high intake of fat, sugar and salt, smoking, and alcoholism <sup>11</sup>. On the opposite hand, high dietary intake of fruit, vegetables and fibre is associated with lower blood level pressures.

Since all these factors are also known to affect gut Microbiota composition, with a special emphasis on dietary choices <sup>12</sup>, it is reasonable to postulate that gut dysbiosis is linked to regulating blood pressure and to preventing or treating hypertension.

In fact, one of the most important roles of the gut Microbiota is to yield energy and nutrients (metabolites and vitamins) by digesting dietary fibre, working symbiotically with the human body.

The consumption of a diet richer in fibre causes an increase in gut Microbiota that generates short-chain fatty acids, mainly by fibre fermentation <sup>13</sup>, and is associated with a decrease in the incidence of cardiovascular disease and high blood pressure levels <sup>14</sup>, even if the magnitude and type of effect is dependent on the type of ingested dietary fibre.

The main short-chain fatty acids that are produced are Acetate, Propionate and Butyrate and their relative percentage changes according to the qualitative and quantitative composition of the Microbiota present in the gut.

Butyrate is mainly used locally by colonocytes to maintain the integrity of the intestinal barrier and to lower inflammatory levels. Acetate and small quantities of both Butyrate and Propionate (metabolised in the liver) enter systemic circulation and reach organs that regulate blood pressure. <sup>15</sup>

The vast majority of the published studies that link gut dysbiosis with high blood pressure levels was performed in animal studies and therefore must be observed with caution when translating results and inferences to humans.

The first studies, published more than 40 years ago, described that germ free rats presented a decreased microvasculature response to catecholamine and a lower cardiac output than control rats <sup>16</sup>.

Other studies, performed in hypertension genetic models, reported changes in the composition of gut Microbiota composition (namely in the *Firmicutes*-to-*Bacteroidetes* ratio, arguably the most described marker of dysbiosis), presenting a reduced number of species that produce Acetate and Butyrate, and an increased percentage of lactate producers <sup>17</sup>.

The same research group performed Microbiota diversity analysis in a cohort of controls, a cohort of pre-hypertensive and a cohort of patients with primary hypertension. Interestingly they found no significant differences between

Microbiota diversity for the pre-hypertension and the primary hypertension cohorts, and did find that these groups presented a decreased microbial richness and diversity, a *Prevotella*-dominated gut enterotype, a distinct metagenomic composition of reduced bacteria associated with healthy status and overgrowth of bacteria such as *Prevotella* and *Klebsiella*, and a disease-linked microbial function <sup>18</sup>. The fact that pre-hypertension and primary hypertension groups presented similar gut Microbiota patterns alerts us to the potential use of gut dysbiosis as an early marker for cardiovascular disease.

In the same paper <sup>19</sup>, the authors conducted a faecal transplantation from hypertensive human donors to germ-free mice, elevated blood pressure was observed to be transferrable through Microbiota, and the direct influence of gut Microbiota on blood pressure of the host was demonstrated. Facts like this not only strengthen the association between gut dysbiosis and hypertension, but also should be taken into account when conducting faecal transplantation in humans.

The increase in blood pressure in spontaneously hypertensive rat was associated with gut pathology that included increased intestinal permeability and decreased tight junction proteins, but in this study pre-hypertensive rats presented similar profiles to that of control ones, with *Firmicutes*-to-*Bacteroidetes* dysbiosis being evident only for the hypertensive group <sup>20</sup>.

Reduced Microbiota richness had also been demonstrated in animal models of hypertension, like the angiotensin II induced hypertensive mice with a decrease in *Bacteroidetes* when compared to sham-salt mice, but a higher prevalence of *Proteobacteria* and *Cyanobacteria* <sup>17</sup>.

The importance of salt in hypertension is well established. The proximal colon is a primary site for gut Microbiota and an important site for dietary absorption. The role played by gut Microbiota was investigated using rats genetically modified either to be sensitive to or resistant to high salt intake diets. These authors observed a gut Microbiota composition difference between the sensitive and the resistant strains, with a higher prevalence of *Bacteroidetes* for the

sensitive group, a lower level of faecal bacteria of the family *Veillonellaceae* and increased plasma acetate and heptanoate were features associated with the increased blood pressure observed in the sensitive rats given resistant rat Microbiota compared with the S rats given S rat Microbiota, indicating a plausible link between microbial content and blood pressure regulation <sup>18,19,20</sup>.

A case-control study of the association between Metabolome, the global collection of all low molecular weight metabolites that are produced by cells during metabolism, and Hypertension Risk identified multiple metabolites associated with hypertension risk. For example, higher levels of lyxose, a fermentation product of gut microbes, were associated with higher risk of hypertension, strengthening the thesis that gut Microbiome plays an important role in the pathogenesis of hypertension <sup>21</sup>.

Besides those metabolites, short chain fatty acids produced by bacteria are also known to mediate arterial resistance <sup>22</sup>, which is consistent with findings indicating that Acetate and Propionate reduce blood pressure levels in animal models, mainly due to a combination of actions in renal mechanisms <sup>23</sup>.

The association between gut dysbiosis seems to be ever more clear, even if causality or consequence is yet to be established and understood. More and more studies are being conducted in this field and there is also evidence being gained of prebiotics and probiotics impact in regulating blood pressure. Preliminary data also seems to suggest interaction between gut Microbiota composition and blood pressure drug's effectiveness.

### 2.1.2 GUT MICROBIOME AND DYSLIPIDAEMIA AND ATHEROSCLEROSIS

Dyslipidaemia is an elevation of plasma low-density lipoprotein (LDL) cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein (HDL) level.

Due to the fact that gut Microbiota is directly involved in the lipid metabolism, it is understandable that it plays a role in dyslipidaemia.

The colonic fermentation of carbohydrates and fibre produces short-chain fatty acids (SCFA), which may impact a number of physiological processes related to human energy metabolism, including satiety, hepatic lipogenesis, adipocyte fat deposition and thermogenesis <sup>24</sup>. Also, a variety of signalling molecules produced by gut bacteria potentially affect hepatic lipid and bile metabolism, reverse cholesterol transport, energy expenditure, and insulin sensitivity in peripheral tissues, thus playing a major role in many metabolic pathways <sup>25</sup>.

Associations have been established between gut Microbiota and the levels of serum triglycerides and HDL cholesterol, as well as between a total of 34 intestinal bacteria taxonomies and body mass index (BMI) and blood lipids. The gut Microbiome appears to make a significant contribution to the variance seen in individual BMI and to the blood levels of triglycerides and HDL, beyond that of clinical risk factors and genetics, whilst manifesting little effect on LDL or TC levels <sup>26</sup>.

Other studies confirmed not only previously known associations between obesity and certain bacterial taxa (such as *Akkermansia*, *Christensenellaceae*, and *Tenericutes*), but also that some of the associations with microbial composition were shared between BMI and levels of triglycerides and HDL and novel associations with *Eggerthella*, *Pasteurellaceae*, and *Butyricimonas* <sup>27</sup>.

Interestingly, only weak correlations were found between Microbiota variation and total cholesterol or LDL cholesterol levels, suggesting that gut Microbiota intervenes more specifically in other lipoproteins <sup>25</sup>.

Another consequence described, effects on reverse cholesterol transport – a crucial atheroprotective function of HDL –, could subsequently influence the development of atherosclerosis <sup>28</sup>.

Modulation of gut Microbiota using different strategies has proved efficient in either repairing gut dysbiosis, but also in treating dyslipidaemias. Soluble fibres, like Polydextrose (PDX), present lipid lowering effects. PDX reduces triglycerides and cholesterol by influencing the gut Microbiota, which in turn modulates intestinal gene expression. In mice fed with western diet PDX promoted systemic changes via regulation of the gut Microbiota and gene expression in intestinal



tract <sup>29</sup>. Faecal transplants and the use of other prebiotics and probiotics have also proved to be effective. This suggests that the gut Microbiota can be a concomitant target for treating dyslipidaemias and other vascular related disease.

Atherosclerosis is a condition where the arteries become narrowed and hardened due to a build-up of plaque lining their walls and is directly related to lipid levels and inflammation.

Gut Microbiota changes have also been found between patients suffering from atherosclerotic cardiovascular disease (ACVD) and healthy controls. An abundance of differences was found between the two groups in major genera of the gut Microbiome, such as a relative reduction in *Bacteroides* and *Prevotella*, enrichment in *Streptococcus* and a higher proportion of *Enterobacteriaceae* (including *Escherichia coli*, *Klebsiella spp.*, and *Enterobacter aerogenes*) in ACVD patients <sup>30</sup>. The same authors described a reduced potential for the synthesis of tetrahydrofolate and altered potential for homocysteine metabolism in the gut microbiome of ACVD patients compared with controls.

Factors like trimethylamine N-oxide (TMAO), trimethylamine (TMA)-Lyases (choline, betaine, carnitine) and other bacterial virulence factors play an important role also on the severity and intensity of atherosclerotic cardiovascular disease. Dietary supplementation of mice with choline, TMAO or betaine promoted upregulation of multiple macrophage scavenger receptors linked to atherosclerosis, and supplementation with choline or TMAO promoted atherosclerosis <sup>31</sup>.

Microbiota is involved in atherosclerosis via different pathways. Gut permeability and translocation of bacteria and their metabolites (LPS) into the circulation occur as a result of gut dysbiosis. The elevated levels of the circulating LPS promote inflammation and foam cell formation <sup>32</sup>.

This increased knowledge of gut Microbiota changes and atherosclerotic cardiovascular disease opens space to identification of early disease biomarkers and to new therapeutic targets.

### 2.1.3. GUT MICROBIOME AND MYOCARDIAL INFARCTION AND STROKE

Atherosclerosis, dyslipidaemias and a combination of environmental and genetic factors are on the genesis of events like myocardial infarction and stroke that are worldwide amongst the leading causes of morbidity and mortality.

Since cardiovascular diseases are strongly influenced by dietary styles which also strongly affect the gut Microbiota and since gut Microbiota is, in turn, known to influence lipid metabolism, insulin resistance, and inflammation, it is of little surprise that there is an association between gut Microbiota and both myocardial infarction and stroke.

In fact, Zunini Vahed et al <sup>32</sup> elegantly described disturbed Microbiota as an enemy for the cardiovascular system, responsible for an increased incidence and severity of cardiovascular disease.

**Trimethylamine** N-oxide induces platelets hyper-reactivity and consequently creates a pro-thrombotic status. It may also induce gut Microbiota dysbiosis. On the other hand, gut Microbiota plays a major role in the generation of TMAO via conversion of dietary nutrients that possess a TMA moiety (such as choline, phosphatidylcholine, and L-carnitine) into TMA by specific microbial choline trimethylamine lyases <sup>8</sup>.

A mechanistic link between the gut Microbiota and the severity of myocardial infarction has been reported in animal models where antibiotic-induced changes in the abundance of individual groups of intestinal Microbiota dramatically altered the host's metabolism. The most affected pathway was the catabolism of the aromatic amino acids phenylalanine, tryptophan and tyrosine and resulted in the decreased severity of an induced myocardial infarction <sup>33</sup>.

Gut Microbiota also seems to attenuate post myocardial infarction events by means of modulating inflammatory and immune response, attenuating post infarction vulnerability to apoptosis and depression, and delaying post-infarction heart failure <sup>32</sup>.

Again, gut Microbiota modulation strategies can prove effective in successfully treating these pathologies.

## 2.2 GUT MICROBIOME AND OBESITY

World Health Organization defines overweight and obesity as abnormal or excessive fat accumulation that may impair health. Obesity is considered an epidemic disease in developed and developing countries and is escalating in all population groups. Some possible explanations include increases in energy intake, changes in the composition of diet, reduced physical activity, and changes in the gut Microbiome <sup>34</sup>.

The relation between gut Microbiota and obesity has been the focus of several investigations. It has been shown that the gut Microbiota influences energy balance by producing SCFA from complex polysaccharides either by digestion or fermentation (together with residual proteins that cannot be digested by human enzymes; this also creates branched-chain fatty acids, gases, and other metabolites). Acetate (C2), Propionate (C3) and Butyrate (C4) are the main products with impact on health <sup>35</sup>.

Obese patients often present with intestinal dysbiosis, creating changes in the quali-quantitative composition of intestinal commensal bacteria, reversible through weight loss.

In obesity, gut Microbiota usually shows decreased diversity, a decreased *Bacteroidetes*-to-*Firmicutes* ratio (with increased capacity to harvest energy from diet), and altered fermentation products (mainly SCFA).

It is also known that long-term diet habits influence the composition of gut Microbiota <sup>36</sup>. Intestinal bacteria react to daily dietary fat and carbohydrates, changing their metabolic pattern. Still, the extent, mechanisms and consequences of a dietary shift remain unknown <sup>37</sup>.

Such studies imply the participation of SCFA production in obesity (by sourcing extra energy). However, SCFA are also responsible for opposite mechanisms of energy expenditure, such as the production of anorectic hormones and appetite regulation, that may prevail in a non-obese person.

Furthermore, the chronic inflammation linked to obesity is associated with changes in Microbiota composition and intestinal permeability <sup>38</sup>, in mechanisms yet to be understood, but that can eventually be used to prevent and to treat these disorders.

For research purposes germ-free mice were inoculated with normal gut microbial cells from conventionally raised mice, which resulted in a 60% increase in body fat and insulin resistance, even with a 27% reduction in food intake. They also found that bacterial colonization increased the storage of triglycerides in the adipocytes of the inoculated mice <sup>39</sup>.

Other authors also performed a study in which germ-free mice were colonized by faecal Microbiota of twins discordant for obesity or by cultured collection of lean or obese animals. Faecal cultured or uncultured faeces of obese animals originate significantly higher increase in body mass and adiposity than those of lean animals, whereas transplanted Microbiota of lean animals was correlated to higher quantity of SCFA in lean animals. When the animals were cohoused (obese and lean) the obese animals stopped their body weight gain modifying also their Microbiota profile like lean animals (increasing *Bacteroides*). The study was also conducted under 2 types of diet (low saturated fat and high saturated fat). The bacterial invasion colonization and phenotype change only occur in low saturated fat diet revealing a diet-dependent mechanism between diet and Microbiota <sup>40</sup>.

Interestingly, not only does the Microbiota, but also the Mycobiota – related to the fungal composition –, seem to be altered in obese individuals <sup>41</sup>.

Even though these studies are quite promising it should be stressed that they were conducted in vitro or in animals and that translation to humans is hard and should be taken carefully. Nevertheless, strategies that modulate the gut microbial composition will be of increasing utility for the treatment of obesity and are expected to enter the clinical practice during the next years.

### 2.3 GUT MICROBIOME AND DIABETES

Diabetes is a worldwide disease whose incidence has been increasing steadily over the last decades. Diabetes is highly influenced by diet and intimately related

to other pathologies described in this review and, therefore, expectedly associated with gut dysbiosis.

Gut Microbiota interferes with diabetes pathogenesis in several ways, including energy metabolism, gut permeability, metabolic endotoxemia and by interacting with the immune system <sup>42</sup>.

The gut Microbiota of patients with type 2 diabetes (T2DM) shows decreased levels of butyrate-producing bacteria (e.g. *F. prausnitzii*) and increased levels of *Firmicutes* and *Proteobacteria* <sup>43</sup>. These changes are accompanied by an increased expression of the Microbiota genes that enhance oxidative stress and inflammation <sup>44</sup>. Likewise, the altered levels of SCFA have implications concerning the inflammatory status.

The decreased levels of *Bifidobacteria* stimulate the secretion of GLP1 and peptide YY that decrease resistance to insulin and enhance the functionality of  $\beta$  cells. These bacteria are also known to reduce intestinal permeability <sup>45</sup>. The marked increase in gut permeability, together with differences in Microbiota composition, has also been associated with the pre-pathological condition of Type 1 Diabetes T1DM <sup>46</sup>. An increase in gut permeability was similarly observed in T2DM patients, a situation that promotes endotoxemia and an increase of the systemic levels of LPS, inducing a deleterious continuous inflammatory state <sup>47</sup>.

*Firmicutes* and *Actinobacteria* metabolize choline, producing metabolites demonstrated to induce Diabetes. The same *Firmicutes* are associated with a decrease in the levels of secondary biliary acids that play an insulin sensitizer role <sup>48</sup>.

T1DM is also associated with gut Microbiota changes. Faecal analysis from these patients showed decreased butyrate-producing bacteria and less butyryl-CoA transferase genes (with a marked decrease in plasma levels of acetate and propionate). The levels of strains *Christensenella* and *Subdoligranulum* correlated with glycemic control, inflammatory parameters and SCFA <sup>49</sup>. Children with beta-cell autoimmunity have also shown low abundance of butyrate-producing bacteria and increased abundance of members of the Bacteroidetes phylum in faecal Microbiota <sup>50</sup>.

Interestingly, metformin, a drug used in the treatment of diabetes, also modulates gut Microbiota <sup>51</sup>.

Compared to participants without diabetes, participants with diabetes taking metformin had higher relative abundance of *Akkermansia muciniphila*, a Microbiota known for mucin degradation, and several gut Microbiota known for the production of SCFAs, including *Butyrivibrio*, *Bifidobacterium bifidum*, *Megasphaera*, and an operational taxonomic unit of *Prevotella* <sup>52</sup>.

The association between gut Microbiota changes and Diabetes opens space not only to early disease biomarkers, but also to new therapeutic strategies, including the use of prebiotics, probiotics and faecal transplantation. Again, further and more robust clinical studies are necessary.

## 2.5 GUT MICROBIOME AND CHRONIC KIDNEY DISEASE

Kidney disease is closely linked to cardiovascular disease and is generally associated to a poorer prognosis of the latter.

Chronic kidney patients' gut Microbiota is significantly different from that of healthy controls, with an increase in pathogenic flora compared to symbiotic flora <sup>53</sup>.

The most frequently described changes in the gut Microbiome of these patients include a reduction of the *Bifidobacteriaceae* and *Lactobacillaceae* levels and an increase of the *Enterobacteriaceae* levels <sup>54</sup>.

Gut dysbiosis, responsible for a disruption of the intestinal epithelial barrier complex can then play an important part in the development of systemic inflammation by enabling the influx of endotoxins and other noxious luminal contents into systemic circulation <sup>55</sup>. Such contents include metabolites like ammonia, indoxyl sulphate and p-cresyl sulphate – associated with poor cardiovascular outcomes <sup>56</sup> –, and some products of the fermentation of undigested foods like sulphates, mainly associated with the family of tryptophanases of the phylum *Bacteroides*.

TMAO, a gut-microbial-dependent metabolite of dietary choline, phosphatidylcholine (lecithin), and L-carnitine, is elevated in chronic kidney disease and is also a good biomarker for cardiovascular disease, as it is an important regulator of fibrosis <sup>57</sup>.

Modulation of the gut Microbiome composition in chronic kidney disease, either by prebiotics, probiotics or even selective antibiotics, may contribute to a decreased accumulation of gut-derived uremic toxins, high circulating level of lipopolysaccharides and immune deregulation, all of which play a critical role in the pathogenesis of chronic kidney disease and its complications <sup>58</sup>.

## 2.6 GUT MICROBIOME AND LIVER DISEASE

Due to its anatomical location and physiological activity, the liver is in a key position to interact with gut Microbiota and the metabolites it generates. The liver receives 70% of its blood supply from the intestine, via the portal vein, and bile acids have been shown to facilitate the communication between the intestine and the liver <sup>59</sup>.

Of all liver pathologies, non-alcoholic fatty liver disease appears to be one of the most directly associated with gut dysbiosis.

Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in developed countries, has two main clinical phenotypes: non-alcoholic fatty liver (hepatic steatosis with minimal lobular inflammation) and non-alcoholic steatohepatitis (NASH, ballooning hepatocellular injury and an initial distinctive fibrosis pattern of perisinusoidal fibrosis surrounding the central veins <sup>60</sup>). It has been described as directly related to other pathologies like the metabolic syndrome, diabetes, and a combination of genetic and environmental factors like diet and lifestyle <sup>61</sup>.

The gut Microbiota has been linked to non-alcoholic fatty liver disease in several ways. Altered gut Microbiota can activate the innate immune system, as it is an inducer of proinflammatory T helper 17 cells and regulatory T cells in the

intestine <sup>61</sup>; it can also make the intestinal barrier more permeable, allowing the passage of bacterial products into the blood stream <sup>62</sup>.

Changes in gut Microbiome may also be the direct cause of hepatic inflammation. On the one hand, increased populations of gut *Enterobacteriales* and *Escherichia coli* generate LPS <sup>63</sup> which in turn interact with Toll-like receptors (TLRs), ultimately inducing cellular death; on the other hand, the previously referred increase in intestinal permeability raises the endotoxins load in portal circulation, promoting hepatic inflammation <sup>64</sup>. This constant inflammation is responsible for activating the inflamassome in a two-step process that generates a heavy hepatic inflammatory response <sup>65</sup>.

Another crucial factor in liver steatosis is obesity, also well connected to gut dysbiosis and to changes in microbial induced metabolism (as described elsewhere in this review). The heavy lipid load associated with obesity acts as a cell stress inducer that activates the immune system. Also contributing to gut dysbiosis are the increased dietary levels of carbohydrates and fat, leading to lesser microbial diversity and to decreased *Bacteroidetes* levels relative to *Firmicutes* <sup>66</sup>. Furthermore, the chronic inflammation linked to obesity is associated with changes in Microbiota composition and intestinal permeability <sup>38</sup>, in mechanisms yet to be understood, but that can eventually be used to prevent and treat this type of diseases. Additionally, in processes directly linked to the obesity pathways, exercise has demonstrated to be an effective non-pharmacological treatment for NAFLD.

Hepatic fibrosis is the main component of tissue remodelling eventually leading to cirrhosis, condition in which the liver does not function properly due to long-term damage. The process of fibrosis is linked to the Microbiota again via the TLR that not only signal for an increased expression of chemokines and adhesion molecules, but also, when activated, down-regulate the activin membrane bound receptor (BAMBI) and remove the fibrogenic brake thus facilitating disease progression <sup>67</sup>.



Many studies revealed differences in Microbiota composition between controls and patients with fatty liver disease. While *Bacteroidetes* and *Firmicutes* remain the dominant phyla among NAFLD patients, their proportional abundance and genera detection vary among different studies <sup>68</sup>. *Proteobacteria* seem to play a protective role regarding steatosis while bacteria from the *Firmicutes* phylum are correlated to higher fatty liver disease risk <sup>69</sup>. Different studies associated *Bacteroides* to NASH and *Ruminococcus* to significant fibrosis. NAFLD severity associates with gut dysbiosis and a shift in metabolic function of the gut Microbiota <sup>70</sup>.

Several other studies demonstrated an association between changes in the gut Microbiome and liver disease. It should however be emphasized that association is very different from causality and from a complete understanding of the underlying mechanisms and pathological pathways. Also many of the studies were performed either in animal models or in small human cohorts and using different methods; therefore, translation to clinic should be cautiously performed.

That said, it is unequivocal that gut Microbiota analysis adds information to classical predictors of NAFLD severity and suggests novel metabolic targets for pre-/probiotics therapies. Strategies like the increase in the consumption of fibre like pectin or probiotic treatment have been successfully studied <sup>62</sup>, but are yet far from being used standardly in the clinics. Absorbable, enteral-active antibiotics like polymixin B and neomycin have also been studied for the treatment of dysbiosis and influence the outcome of chronic liver disease or cirrhosis <sup>71</sup>.

Probiotics like *Lactobacillus* are the components of many commercially available multispecies formulations such as VSL#3. In the rat gut, VSL#3 fortifies the intestinal barrier by increasing the amount of secreted mucus and upregulating Muc2 in the colon and occludin levels in the ileum <sup>72</sup>. Faecal transplants, however controversial, have also demonstrated to be effective and helpful when dealing with fatty liver disease.

By now, it is clear that gut Microbiome plays an important role in liver disease even if the pathophysiological mechanisms are not yet fully understood.

Precision medicine and the targets and prevention methods that will arise from the continuous study of this area will certainly bring new therapeutic tools in the next years.

## 2.7 GUT MICROBIOME AND INTESTINAL DISEASE

The effect of gut Microbiota dysbiosis in intestinal disease is probably the most logical, due to the local effect of the Microbiota. The best example that comes to mind is diarrhoea, a pathology in which gut Microbiota plays a major role in several ways, not only as cause, but also with protective effects <sup>73</sup>.

Another frequent intestinal problem is constipation. Growing evidence indicates that alterations of intestinal Microbiota may contribute to constipation and constipation-related symptoms, namely by modulating gut mobility <sup>74</sup>. Differences in the composition of the intestinal Microbiota have been demonstrated when constipated patients and healthy controls were compared. Probiotics are frequently and successfully used for constipation treatment or prevention.

Several studies have reported differences between the Microbiota of inflammatory bowel disease (IBD; like Crohn disease and ulcerative colitis) patients and healthy subjects. A lower microbial diversity was found in IBD patients with an emphasis in a decrease of the *Firmicutes* quantity and an increase in the taxa belonging to the *Proteobacteria* phylum, generally associated with an increase in facultative anaerobes <sup>75</sup>. The reduction in this species lowers the production of SCFA increase regulatory T cells, which support immune tolerance and also have anti-inflammatory effects. This outgrowth of facultative anaerobic organisms may be driven by a change in the gut redox potential associated to the chronic inflammatory status <sup>76</sup>. A special role seems to be played by *F. Prausnitzii*, known to induce the production of IL-10 and inhibit the production of inflammatory cytokines, such as IL-12 and IFN- $\gamma$  <sup>77</sup>, whose significantly lower levels in IBD lead to an increased probability of disease recurrence.

Colorectal cancer, another high prevalence intestinal pathology, is also strongly influenced by gut Microbiota <sup>78</sup>. This paper addresses the influence of dietary

patterns, fibre consumption, dietary supplements and concomitant disease on the Microbiota composition, and studied bacterial metabolites and how they can disrupt the gut barrier integrity and challenge immune homeostasis, increasing the probability of cancer.

The ever growing knowledge on gut Microbiota and its association with several intestinal pathologies opens new space for the identification of early biomarkers and for new therapeutic targets and strategies that will likely increase the life quality of these patients.

Arguably the most successful case of treating intestinal disease using gut Microbiota is the treatment of multi-resistant *Clostridium difficile* infection (CDI) using faecal Microbiota transplantation. CDI is a worldwide leading cause of mortality and morbidity and is becoming more and more resistant to antibiotics. This procedure, not yet fully regulated by the medicines agencies, has proven to be extremely effective in cases where administration of antibiotics failed. Strategies for performing effective treatments using faecal transplants were described in detail in papers like the ones referred by Dowle <sup>79</sup> and range from colonoscopy administration of enemas to oral administration of lyophilized contents inserted in capsules.

Faecal Microbiota transplantation (FMT) is emerging as a treatment option in the United States of America and in Europe, and a conference consensus paper <sup>80</sup> was recently published on this thematic. In the supplement of that paper other applications for FMT are evaluated even if they are not as strongly adequate as for refractory CDI treatment. These include Crohn disease and Irritable Bowel Syndrome.

## 2.8 GUT MICROBIOME AND CNS RELATED DISEASES

The connection between the gut and the central nervous system may not appear to be a direct one, but since the definition of the so-called gut-brain axis it is becoming more and more discussed and studied.

The first time an association between gut Microbiota and brain disease was reported was in the early 20th century, when the administration of lactic acid was tested in the treatment of depressive symptoms <sup>81</sup>.

Perhaps the most evident established connection was between gut Microbiota and stroke/ischemic brain damage. As previously described, these patients may present some Microbiota alterations (namely decreased diversity, decreased levels of *Bacteroides*, increased *Atopobium* levels and changes in the microbial metabolism <sup>82</sup>), all of which are responsible for an increase in gut permeability, with consequent systemic inflammation and increased risk of infection, as well as an increased risk for thrombosis, due to an increase in the levels of TMAO<sup>83</sup>. Also, the composition of gut Microbiota is likely to affect the level of neuroinflammation by modulating T Cells and IL-17 levels <sup>84</sup>.

Gut Microbiota is known not only to intervene in the synthesis of GABA, noradrenaline and dopamine, but also in the production of SCFA, that also present neuroactive actions. The fact that gut Microbiota plays such a key role in modulating neurotransmitters helps explain the fact that gut dysbiosis interfere in disorders like anxiety and depression. Neurotransmitters play a major role in several central nervous related diseases.

Gut Microbiota dysbiosis has been reported in preclinical data <sup>85</sup> and also in patients diagnosed with depression <sup>86</sup>, namely by a noticeable decrease in microbial diversity. Prebiotics like galactooligosaccharide (GOS) have been found to be effective in reducing activation of the preclinical models of anxiety and depression and also in lowering cortisol levels in human volunteers <sup>87</sup>. Probiotics like *B. longum* effectively increased scores of depression even if it did not affect anxiety levels <sup>88</sup>. Evidence of the association between gut Microbiota and other psychiatric disorders was also found during faecal transplant procedures <sup>89</sup>; yet, there is still need for more robust clinical data.

Attention-deficit/hyperactivity disorder (ADHD) is associated with abnormalities in dopamine neurotransmission. The role of gut Microbiota is not clear, but a nominal increase in the *Bifidobacterium* genus was observed in ADHD cases with metagenomic revealing an increase in the bacterial gene

functionality encoding cyclohexadienyl dehydratase, an enzyme involved in the synthesis of phenylalanine, a dopamine precursor <sup>90</sup>.

Gut Microbiota dysbiosis is also associated with a variety of neurodegenerative diseases like Alzheimer, Parkinson and Multiple Sclerosis.

In Parkinson, a degenerative disorder primarily affecting dopaminergic neurons of the substantia nigra, gastrointestinal dysfunction is frequently noticed before motor symptoms. Also,  $\alpha$ -synuclein protein aggregates, characteristic of Parkinson disease, are also found in the enteric nervous system. Some parkinsonian patients present a decrease in the *Prevotella* species, combined with an increase in the *Akkermansia muciniphilia* <sup>91</sup>. The *Prevotella* species produces mucin that limits intestinal permeability and therefore helps prevent bacteria translocation to systemic circulation. A different study <sup>92</sup> demonstrated higher levels of proinflammatory bacteria and lower levels of anti-inflammatory bacteria in Parkinson patients compared to healthy controls. The accumulating preclinical and clinical data suggest that the Microbiota-gut-brain axis may be an interesting additional target for Parkinson therapeutics.

Alzheimer, also a neurodegenerative disease, is characterized by the accumulation of amyloid plaques and tau fibrils in the brain. It has been associated with gut Microbiota dysbiosis either in preclinical or clinical studies. Again, an increase in the levels of bacteria associated with inflammation was found, combined with an increase in intestinal permeability, suggesting that gut Microbiota plays an important role in the earlier stages of the neuroinflammation associated with Alzheimer <sup>93</sup>. Evidence is growing that intervening in the Microbiota-gut-brain axis, either with prebiotics, probiotics or dietary changes can ameliorate this neurodegenerative disease.

Another high prevalence neurodegenerative disease is Multiple Sclerosis (MS), characterized by the progressive loss of myelin in axons. Similarly to other neurodegenerative diseases, an increase in intestinal permeability was found in MS patients, allowing an increase in the translocation of bacteria and LPS to the systemic circulation and thus increasing systemic inflammation <sup>94</sup>. Additionally,

when compared to healthy controls, MS patients presented lower levels of *Faecalibacterium*, *Prevotella* and *Anaerostipes* and a striking depletion of species belonging to the *Clostridia* XIVa and IV Clusters <sup>95</sup>.

Gut Microbiota dysbiosis was also associated with psychiatric pathologies like schizophrenia whose patients showed significant correlations between increases in *Lactobacillus* group bacteria and the severity of different symptom domains <sup>96</sup>.

The ever-growing information regarding the Microbiota-gut-axis, both in characterization and in mechanistic pathways, opens doors to the identification of early biomarkers and new therapeutic targets that can be used to treat or ameliorate central nervous systems diseases. Gut Microbiota modulation, though in need of more robust clinical data, presents itself as a promising strategy.

## 2.9 GUT MICROBIOME AND OTHER PATHOLOGIES

Several other pathologies have been associated to significant changes in gut Microbiota even though it is not clear if the dysbiosis is their cause or their consequence, or even the extension to which it affects the pathology.

Ankylosing spondylitis (AS) is a type of arthritis that is referred to a group of chronic immune-mediated inflammatory diseases termed as seronegative spondyloarthropathies or spondyloarthritis. Even if the mechanisms remain unclear, there is some evidence that gut Microbiota and the IL-23/IL-17 pathway are pivotal in the pathogenesis of spondyloarthritides <sup>97</sup>. A similar association was found between gut dysbiosis and rheumatoid arthritis (RA). There is also growing evidence that different drugs, such as antibiotics and immunosuppressants, can influence and be influenced by the Microbiota in RA and AS patients <sup>98</sup>.

Recently, suggestions arose of the involvement of a gut-retina axis in the protection against dietary glycemia-induced age-related macular degeneration (AMD). Metabolomics revealed microbial co-metabolites, particularly serotonin,

as protective against AMD and *Bacteroidales* as protective towards the development of the disease <sup>99</sup>.

Choroidal neovascularization can also be aggravated by gut Microbiota dysbiosis. Gut dysbiosis known effects of heightened intestinal permeability and chronic low-grade inflammation, characteristic of inflammaging, associated with elevated production of IL-6, IL-1 $\beta$ , TNF- $\alpha$ , and VEGF-A, ultimately aggravate pathological angiogenesis <sup>100</sup>.

Gut Microbiota dysbiosis has also been associated with dermatological diseases like atopic dermatitis <sup>101</sup> and eczema <sup>102</sup>, as well as with other several allergies related pathologies, mainly due to mechanisms of mucosal immune tolerance <sup>103</sup>.

Finally, another very interesting effect of gut Microbiota is the influence it plays in the effectiveness of drugs. The first studies of alterations in drug effectiveness are now published and demonstrate that gut Microbiota is an additional factor that should be taken into consideration when prescribing a drug. This interaction has been demonstrated in chemotherapeutics <sup>104</sup>, antihypertensive drugs <sup>105</sup>, antibiotics <sup>106</sup> and immunotherapeutics <sup>107</sup>, and is naturally expected to interfere with many other drugs and therapeutic processes.

### 3 - CONCLUSION

The impact of Microbiome and Microbiota on numerous diseases has been increasingly documented in the last decade.

It remains doubtful if dysbiosis is a cause or a consequence of those diseases, and to which extension it may affect clinical result. Nevertheless, the Microbiota is now being considered a “virtual organ”, with its metabolic and immune relevance becoming ever more clear and increasingly taken into consideration in the clinical approach.

As such, several Microbiota modulation strategies have been suggested, including the use of prebiotics, probiotics, antibiotics, dietary changes and faecal transplant, all with moderate success. For some of these strategies the regulatory framework is developing together with the knowledge increase.

Also, the interaction between Microbiota and administered medication is now being considered, as clinical data demonstrate that drug effectiveness is also dependent on the Microbiota composition.

More robust and powerful clinical studies are being performed or planned in order to better understand the impact of Microbiota and its modulation. Preclinical data is of extreme relevance but translation to humans needs to be done carefully. New analytical techniques, more sensitive and more precise, will similarly improve our insight into its role in the health status of an individual, not only regarding bacterial composition, but also the importance of fungi, virus and phages.

#### 4 - REFERENCES

1. Huttenhower C, Gevers D, Knight R, et al. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207-214. doi:10.1038/nature11234
2. Human Microbiome Project Consortium THMP. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207-214. doi:10.1038/nature11234
3. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. *Nature*. 2012;488(7410):178-184. doi:10.1038/nature11319
4. Sankar SA, Lagier J-C, Pontarotti P, Raoult D, Fournier P-E. The human gut microbiome, a taxonomic conundrum. *Syst Appl Microbiol*. 2015;38(4):276-286. doi:10.1016/j.syapm.2015.03.004
5. Rajilić-Stojanović M, Heilig HGHJ, Molenaar D, et al. Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environ Microbiol*. 2009;11(7):1736-1751. doi:10.1111/j.1462-2920.2009.01900.x
6. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013;500(7464):541-546. doi:10.1038/nature12506



7. WHO | Cardiovascular diseases (CVDs). WHO. 2017. <http://www.who.int/mediacentre/factsheets/fs317/en/>. Accessed January 26, 2018.
8. Tang WHW, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. *Circ Res*. 2017;120(7):1183-1196. doi:10.1161/CIRCRESAHA.117.309715
9. Ahmadmehrabi S, Tang WHW. Gut microbiome and its role in cardiovascular diseases. *Curr Opin Cardiol*. 2017;32(6):761-766. doi:10.1097/HCO.0000000000000445
10. Bakris G, Sorrentino M. Redefining Hypertension — Assessing the New Blood-Pressure Guidelines. *N Engl J Med*. January 2018:NEJMp1716193. doi:10.1056/NEJMp1716193
11. Tzoulaki I, Elliott P, Kontis V, Ezzati M. Worldwide Exposures to Cardiovascular Risk Factors and Associated Health Effects. *Circulation*. 2016;133(23):2314-2333. doi:10.1161/CIRCULATIONAHA.115.008718
12. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. *Nat Immunol*. 2011;12(1):5-9. doi:10.1038/ni0111-5
13. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut*. 1987;28(10):1221-1227. <http://www.ncbi.nlm.nih.gov/pubmed/3678950>. Accessed January 25, 2018.
14. Threapleton DE, Greenwood DC, Evans CEL, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ*. 2013;347:f6879. doi:10.1136/BMJ.F6879
15. Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. *Nat Rev Cardiol*. 2017;15(1):20-32. doi:10.1038/nrcardio.2017.120
16. Baez S, Gordon HA. Tone and reactivity of vascular smooth muscle in germfree rat mesentery. *J Exp Med*. 1971;134(4):846-856. <http://www.ncbi.nlm.nih.gov/pubmed/4329047>. Accessed January 25, 2018.
17. Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. *Hypertens (Dallas, Tex 1979)*. 2015;65(6):1331-1340. doi:10.1161/HYPERTENSIONAHA.115.05315

18. Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome*. 2017;5(1):14. doi:10.1186/s40168-016-0222-x
19. Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome*. 2017;5(1):14. doi:10.1186/s40168-016-0222-x
20. Santisteban MM, Qi Y, Zubcevic J, et al. Hypertension-Linked Pathophysiological Alterations in the Gut Novelty and Significance. *Circ Res*. 2017;120(2):312-323. doi:10.1161/CIRCRESAHA.116.309006
21. Hao Y, Wang Y, Xi L, et al. A Nested Case-Control Study of Association between Metabolome and Hypertension Risk. *Biomed Res Int*. 2016;2016:1-7. doi:10.1155/2016/7646979
22. Mortensen F V, Nielsen H, Mulvany MJ, Hesse I. Short chain fatty acids dilate isolated human colonic resistance arteries. *Gut*. 1990;31(12):1391-1394. <http://www.ncbi.nlm.nih.gov/pubmed/2265780>. Accessed January 26, 2018.
23. Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. *Proc Natl Acad Sci*. 2013;110(11):4410-4415. doi:10.1073/pnas.1215927110
24. Fava F, Gitau R, Griffin BA, Gibson GR, Tuohy KM, Lovegrove JA. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome “at-risk” population. *Int J Obes*. 2013;37(2):216-223. doi:10.1038/ijo.2012.33
25. Ghazalpour A, Cespedes I, Bennett BJ, Allayee H. Expanding role of gut microbiota in lipid metabolism. *Curr Opin Lipidol*. 2016;27(2):141-147. doi:10.1097/MOL.0000000000000278
26. Fu J, Bonder MJ, Cniti MC, et al. The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. *Circ Res*. 2015;117(9):817-824. doi:10.1161/CIRCRESAHA.115.306807
27. Everard A, Belzer C, Geurts L, et al. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A*. 2013;110(22):9066-9071. doi:10.1073/pnas.1219451110

28. Nakaya K, Ikewaki K. Microbiota and HDL metabolism. *Curr Opin Lipidol.* 2018;29(1):18-23. doi:10.1097/MOL.0000000000000472
29. Raza GS, Putaala H, Hibberd AA, et al. Polydextrose changes the gut microbiome and attenuates fasting triglyceride and cholesterol levels in Western diet fed mice. *Sci Rep.* 2017;7(1):5294. doi:10.1038/s41598-017-05259-3
30. Jie Z, Xia H, Zhong S-L, et al. The gut microbiome in atherosclerotic cardiovascular disease. *Nat Commun.* 2017;8(1):845. doi:10.1038/s41467-017-00900-1
31. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature.* 2011;472(7341):57-63. doi:10.1038/nature09922
32. Zununi Vahed S, Barzegari A, Zuluaga M, Letourneur D, Pavon-Djavid G. Myocardial infarction and gut microbiota: An incidental connection. *Pharmacol Res.* November 2017. doi:10.1016/J.PHRS.2017.11.008
33. Lam V, Su J, Hsu A, Gross GJ, Salzman NH, Baker JE. Intestinal Microbial Metabolites Are Linked to Severity of Myocardial Infarction in Rats. Calvert J, ed. *PLoS One.* 2016;11(8):e0160840. doi:10.1371/journal.pone.0160840
34. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2014;384(9945):766-781. doi:10.1016/S0140-6736(14)60460-8
35. Thompson AL. Developmental origins of obesity: Early feeding environments, infant growth, and the intestinal microbiome. *Am J Hum Biol.* 2012;24(3):350-360. doi:10.1002/ajhb.22254
36. López-Cepero AA, Palacios C. Association of the Intestinal Microbiota and Obesity. *P R Health Sci J.* 2015;34(2):60-64. <http://www.ncbi.nlm.nih.gov/pubmed/26061054>. Accessed January 30, 2018.
37. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. *Nature.* 2012;489(7415):242-249. doi:10.1038/nature11552
38. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol.* 2015;3(3):207-215. doi:10.1016/S2213-8587(14)70134-2

39. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci.* 2004;101(44):15718-15723. doi:10.1073/pnas.0407076101
40. Ridaura VK, Faith JJ, Rey FE, et al. Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. *Science* (80- ). 2013;341(6150):1241214-1241214. doi:10.1126/science.1241214
41. Borges FM, de Paula TO, Sarmiento MRA, et al. Fungal Diversity of Human Gut Microbiota Among Eutrophic, Overweight, and Obese Individuals Based on Aerobic Culture-Dependent Approach. *Curr Microbiol.* January 2018. doi:10.1007/s00284-018-1438-8
42. He C, Shan Y, Song W. Targeting gut microbiota as a possible therapy for diabetes. *Nutr Res.* 2015;35(5):361-367. doi:10.1016/j.nutres.2015.03.002
43. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. *Gut.* 2014;63(9):1513-1521. doi:10.1136/gutjnl-2014-306928
44. Palau-Rodriguez M, Tulipani S, Isabel Queipo-Ortuño M, Urpi-Sarda M, Tinahones FJ, Andres-Lacueva C. Metabolomic insights into the intricate gut microbial–host interaction in the development of obesity and type 2 diabetes. *Front Microbiol.* 2015;6:1151. doi:10.3389/fmicb.2015.01151
45. Velasquez-Manoff M. Gut Microbiome: The Peacekeepers. *Nature.* 2015;518(7540):S3-S11. doi:10.1038/518S3a
46. Maffeis C, Martina A, Corradi M, et al. Association between intestinal permeability and faecal microbiota composition in Italian children with beta cell autoimmunity at risk for type 1 diabetes. *Diabetes Metab Res Rev.* 2016;32(7):700-709. doi:10.1002/dmrr.2790
47. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. *Am J Physiol Metab.* 2007;292(3):E740-E747. doi:10.1152/ajpendo.00302.2006
48. Palau-Rodriguez M, Tulipani S, Isabel Queipo-Ortuño M, Urpi-Sarda M, Tinahones FJ, Andres-Lacueva C. Metabolomic insights into the intricate gut microbial–host interaction in the development of obesity and type 2 diabetes. *Front Microbiol.* 2015;6:1151. doi:10.3389/fmicb.2015.01151

49. de Groot PF, Belzer C, Aydin Ö, et al. Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. Vudattu NK, ed. PLoS One. 2017;12(12):e0188475. doi:10.1371/journal.pone.0188475
50. Vaarala O. Human Intestinal Microbiota and Type 1 Diabetes. Curr Diab Rep. 2013;13(5):601-607. doi:10.1007/s11892-013-0409-5
51. Lee H, Lee Y, Kim J, et al. Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice. Gut Microbes. November 2017:00-00. doi:10.1080/19490976.2017.1405209
52. de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2017;40(1):54-62. doi:10.2337/dc16-1324
53. Cigarran Guldris S, González Parra E, Cases Amenós A. Microbiota intestinal en la enfermedad renal crónica. Nefrología. 2017;37(1):9-19. doi:10.1016/j.nefro.2016.05.008
54. Sampaio-Maia B, Simões-Silva L, Pestana M, Araujo R, Soares-Silva IJ. The Role of the Gut Microbiome on Chronic Kidney Disease. In: Advances in Applied Microbiology. Vol 96. ; 2016:65-94. doi:10.1016/bs.aambs.2016.06.002
55. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine. Curr Opin Nephrol Hypertens. 2012;21(6):587-592. doi:10.1097/MNH.0b013e328358c8d5
56. Vaziri ND, Zhao Y-Y, Pahl M V. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2016;31(5):737-746. doi:10.1093/ndt/gfv095
57. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res. 2017;179:24-37. doi:10.1016/j.trsl.2016.04.007
58. Pan W, Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int Urol Nephrol. August 2017. doi:10.1007/s11255-017-1689-5
59. Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res. 2015;56(6):1085-1099. doi:10.1194/jlr.R054114

60. Kleiner DE. Histopathology, grading and staging of nonalcoholic fatty liver disease. *Minerva Gastroenterol Dietol.* 2018;64(1):28-38. doi:10.23736/S1121-421X.17.02445-X
61. Neuman MG, French SW, French BA, et al. Alcoholic and non-alcoholic steatohepatitis. *Exp Mol Pathol.* 2014;97(3):492-510. doi:10.1016/j.yexmp.2014.09.005
62. Cassard A-M, Ciocan D. Microbiota, a key player in alcoholic liver disease. *Clin Mol Hepatol.* December 2017. doi:10.3350/cmh.2017.0067
63. Ramos-Romero S, Hereu M, Atienza L, et al. Mechanistically different effects of fat and sugar on insulin resistance, hypertension and gut microbiota in rats. *Am J Physiol Metab.* January 2018:ajpendo.00323.2017. doi:10.1152/ajpendo.00323.2017
64. Fu S, Watkins SM, Hotamisligil GS. The Role of Endoplasmic Reticulum in Hepatic Lipid Homeostasis and Stress Signaling. *Cell Metab.* 2012;15(5):623-634. doi:10.1016/j.cmet.2012.03.007
65. Ganz M, Csak T, Nath B, Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. *World J Gastroenterol.* 2011;17(43):4772. doi:10.3748/wjg.v17.i43.4772
66. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature.* 2006;444(7122):1027-1131. doi:10.1038/nature05414
67. Seki E, De Minicis S, Österreicher CH, et al. TLR4 enhances TGF- $\beta$  signaling and hepatic fibrosis. *Nat Med.* 2007;13(11):1324-1332. doi:10.1038/nm1663
68. Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. *Hepatobiliary Pancreat Dis Int.* 2015;14(6):572-581. <http://www.ncbi.nlm.nih.gov/pubmed/26663004>. Accessed January 28, 2018.
69. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. *Hepatology.* 2013;57(2):601-609. doi:10.1002/hep.26093
70. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology.* 2016;63(3):764-775. doi:10.1002/hep.28356

71. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. *Am J Physiol Gastrointest Liver Physiol.* 2016;311(6):G1018-G1036. doi:10.1152/ajpgi.00245.2016
72. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. *Am J Physiol Liver Physiol.* 2007;292(1):G315-G322. doi:10.1152/ajpgi.00265.2006
73. Gilchrist CA, Petri SE, Schneider BN, et al. Role of the Gut Microbiota of Children in Diarrhea Due to the Protozoan Parasite *Entamoeba histolytica*. *J Infect Dis.* 2016;213(10):1579-1585. doi:10.1093/infdis/jiv772
74. Zhao Y, Yu Y-B. Intestinal microbiota and chronic constipation. *Springerplus.* 2016;5(1):1130. doi:10.1186/s40064-016-2821-1
75. Ni J, Shen T-CD, Chen EZ, et al. A role for bacterial urease in gut dysbiosis and Crohn's disease. *Sci Transl Med.* 2017;9(416):eaah6888. doi:10.1126/scitranslmed.aah6888
76. Albenberg L, Esipova T V., Judge CP, et al. Correlation Between Intraluminal Oxygen Gradient and Radial Partitioning of Intestinal Microbiota. *Gastroenterology.* 2014;147(5):1055-1063.e8. doi:10.1053/j.gastro.2014.07.020
77. Sokol H, Pigneur B, Watterlot L, et al. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci.* 2008;105(43):16731-16736. doi:10.1073/pnas.0804812105
78. Song M, Chan AT. Diet, Gut Microbiota, and Colorectal Cancer Prevention: a Review of Potential Mechanisms and Promising Targets for Future Research. *Curr Colorectal Cancer Rep.* 2017;13(6):429-439. doi:10.1007/s11888-017-0389-y
79. Dowle C. Faecal microbiota transplantation: a review of FMT as an alternative treatment for *Clostridium difficile* infection. *Biosci Horizons.* 2016;9:hzw007. doi:10.1093/biohorizons/hzw007
80. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut.* 2017;66(4):569-580. doi:10.1136/gutjnl-2016-313017

81. Bsted AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part II – contemporary contextual research. *Gut Pathog.* 2013;5(1):3. doi:10.1186/1757-4749-5-3
82. Yamashiro K, Tanaka R, Urabe T, et al. Correction: Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. *PLoS One.* 2017;12(4):e0176062. doi:10.1371/journal.pone.0176062
83. Zhu W, Gregory JC, Org E, et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. *Cell.* 2016;165(1):111-124. doi:10.1016/j.cell.2016.02.011
84. Benakis C, Brea D, Caballero S, et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal  $\gamma\delta$  T cells. *Nat Med.* 2016;22(5):516-523. doi:10.1038/nm.4068
85. Kelly JR, Borre Y, O' Brien C, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatr Res.* 2016;82:109-118. doi:10.1016/j.jpsychires.2016.07.019
86. Yu M, Jia H, Zhou C, et al. Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics. *J Pharm Biomed Anal.* 2017;138:231-239. doi:10.1016/j.jpba.2017.02.008
87. Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PWJ. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. *Psychopharmacology (Berl).* 2015;232(10):1793-1801. doi:10.1007/s00213-014-3810-0
88. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic *Bifidobacterium longum* NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. *Gastroenterology.* 2017;153(2):448-459.e8. doi:10.1053/j.gastro.2017.05.003
89. Evrensel A, Ceylan ME. Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders. *Clin Psychopharmacol Neurosci.* 2016;14(3):231-237. doi:10.9758/cpn.2016.14.3.231
90. Aarts E, Ederveen THA, Naaijen J, et al. Gut microbiome in ADHD and its relation to neural reward anticipation. Hashimoto K, ed. *PLoS One.* 2017;12(9):e0183509. doi:10.1371/journal.pone.0183509



91. Bedarf JR, Hildebrand F, Coelho LP, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. *Genome Med.* 2017;9(1):39. doi:10.1186/s13073-017-0428-y
92. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. *Mov Disord.* 2015;30(10):1351-1360. doi:10.1002/mds.26307
93. Cattaneo A, Cattane N, Galluzzi S, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. *Neurobiol Aging.* 2017;49:60-68. doi:10.1016/j.neurobiolaging.2016.08.019
94. Escribano BM, Medina-Fernández FJ, Aguilar-Luque M, et al. Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model. *Neurotherapeutics.* 2017;14(1):199-211. doi:10.1007/s13311-016-0480-0
95. Miyake S, Kim S, Suda W, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. *Wilson BA, ed. PLoS One.* 2015;10(9):e0137429. doi:10.1371/journal.pone.0137429
96. Lv F, Chen S, Wang L, et al. The role of microbiota in the pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting microbiota as a treatment option. *Oncotarget.* 2017;8(59):100899-100907. doi:10.18632/oncotarget.21284
97. Babaie F, Hasankhani M, Mohammadi H, et al. The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. *Immunol Lett.* 2018;196:52-62. doi:10.1016/j.imlet.2018.01.014
98. Picchianti-Diamanti A, Rosado MM, D'Amelio R. Infectious Agents and Inflammation: The Role of Microbiota in Autoimmune Arthritis. *Front Microbiol.* 2018;8:2696. doi:10.3389/fmicb.2017.02696
99. Rowan S, Jiang S, Korem T, et al. Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration. *Proc Natl Acad Sci.* 2017;114(22):E4472-E4481. doi:10.1073/pnas.1702302114

100. Andriessen EM, Wilson AM, Mawambo G, et al. Gut microbiota influences pathological angiogenesis in obesity - driven choroidal neovascularization. *EMBO Mol Med*. 2016;8(12):1366-1379. doi:10.15252/emmm.201606531
101. Lee M-J, Kang M-J, Lee S-Y, et al. Perturbations of the gut microbiome genes in infants with atopic dermatitis according to feeding type. *J Allergy Clin Immunol*. January 2018. doi:10.1016/j.jaci.2017.11.045
102. Zheng H, Liang H, Wang Y, et al. Altered Gut Microbiota Composition Associated with Eczema in Infants. *Planet PJ, ed. PLoS One*. 2016;11(11):e0166026. doi:10.1371/journal.pone.0166026
103. Kozyrskyj AL. Can we predict future allergies from our infant gut microbiota? *Expert Rev Respir Med*. 2015;9(6):667-670. doi:10.1586/17476348.2015.1098538
104. Scott TA, Quintaneiro LM, Cabreiro F. Microbiome genetics underpins chemotherapy. *Oncotarget*. 2017;8(55):93303-93304. doi:10.18632/oncotarget.22066
105. Choi MS, Yu JS, Yoo HH, Kim D-H. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. *Pharmacol Res*. January 2018. doi:10.1016/j.phrs.2018.01.019
106. Kim D-H. Gut Microbiota-Mediated Drug-Antibiotic Interactions. *Drug Metab Dispos*. 2015;43(10):1581-1589. doi:10.1124/dmd.115.063867
107. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science* (80- ). 2018;359(6371):91-97. doi:10.1126/science.aan3706

# ANEXO

Normas de Publicação da Revista Journal of  
International Medical Research

Search: keyword,  
Search



**2016 Ranking:** 208/257 in Pharmacology & Pharmacy | 98/128 in Medicine, Research & Experimental

Source: 2016 Journal Citation Reports® (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE

### Managing Editor

[Matthew Thorne](#)

SAGE Publications Ltd, UK

### Other Titles in:

[Clinical Medicine](#) | [Public Health Education & Health Promotion](#)

eISSN: 14732300 | ISSN: 03000605 | Current volume: 46 | Current issue: 2 | Frequency: Not Yet Specified

[Download flyer](#) [Recommend to Library](#)

Share

- [Description](#)
- [Aims and Scope](#)
- [Editorial Board](#)
- [Abstracting / Indexing](#)
- [Submission Guidelines](#)

1. [Open Access](#)
2. [Open Access publication charge](#)
3. [Article types](#)
4. [Editorial policies](#)
  5. [Peer Review Policy](#)
  6. [Authorship](#)
  7. [Acknowledgments](#)
  8. [Funding](#)
  9. [Declaration of conflicting interests](#)
  10. [Research ethics and patient consent](#)
  11. [Clinical Trials](#)
  12. [Reporting guidelines](#)
  13. [Data](#)
14. [Publishing policies](#)
  15. [Publication ethics](#)
  16. [Contributor's publishing agreement](#)
17. [Preparing your manuscript](#)
  18. [Word processing formats](#)
  19. [Title, keywords and abstracts](#)
  20. [Artwork, figures and other graphics](#)
  21. [Reference style](#)

Search: keyword,  
Search

 0

28. [On acceptance and publication - Technical Edit](#)

29. [Proofs](#)

30. [SAGE Production](#)

31. [Continuous publication](#)

32. [Promoting your article](#)

33. [Further information](#)

This Journal is a member of the [Committee on Publication Ethics](#)

This Journal recommends that authors follow the [Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals](#) formulated by the International Committee of Medical Journal Editors (ICMJE).

**Please read the guidelines below then visit the journal's submission site**

**<https://mc.manuscriptcentral.com/jimr> to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.**

**Only manuscripts of sufficient quality that meet the aims and scope of *Journal of International Medical Research* will be reviewed.**

**As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.**

*Journal of International Medical Research* is a leading international journal for rapid publication of original medical, pre-clinical and clinical research and reviews on a page charge basis.

As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible.

## 1. Open Access

*Journal of International Medical Research* is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of a page charge which is paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

For general information on open access at SAGE please visit the [Open Access page](#) or view our [Open Access FAQs](#).

[\[Return to top\]](#)



Search: keyword,  
Search



[\[Return to top\]](#)

### 3. Article types

*Journal of International Medical Research* welcomes original articles which **demonstrate strong evidence of clinical applicability, are scientifically robust and highly appropriate for an international general medical readership**. The text should be divided into Introduction, Patients & Methods/Materials & Methods, Results, Discussion, Acknowledgements, Declaration of Conflicting Interests and References.

**Case reports** should be of general interest rather than specialist interest. They must be likely to change routine clinical practice in some meaningful way. Rarity alone is not an appropriate criterion for acceptance. Retrospective case record analyses are discouraged and unlikely to be accepted. Case reports should be divided into Introduction, Case Report, Discussion, Acknowledgements, Declaration of Conflicting Interests and References.

**Review articles** and other types of papers may take their own relevant main headings.

**Traditional Chinese Medicine studies** are considered if it is clear what the active ingredient is. It must have been isolated and shown to have an acceptable standard of efficacy and safety through randomized controlled trials.

Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for consideration as Supplements and are subject to peer review.

Studies involving cell cultures and animal models are considered if they are supported by a clinical study.

Please note that small-scale, localized and pilot studies are discouraged and unlikely to be accepted. Replication in a local sample is not a reason for acceptance – the rationale for the study must be demonstrated.

[\[Return to top\]](#)

### 4. Editorial policies

#### 5. Peer review policy

Please explain within your cover letter why you think the paper suitable for publication. Following a preliminary triage to select submissions suitable for ***Journal of International Medical Research***, papers are sent out for external peer review by the Managing Editor to at least two relevant specialists. This process will be executed in a robust fashion but in as short a time as possible. After peer review, the paper may be accepted, revisions requested, or rejected; this decision is taken by the Managing Editor, in consultation with the Consultant Editor when required.

***Journal of International Medical Research*** utilizes a single-blind peer-review process in which the reviewer's name and information are withheld from the author. Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.

If the paper is accepted, the page charge fee is due. After payment is received the next phase is an in-depth, detailed technical edit by two, sometimes three, medical Technical Editors. The editorial and scientific queries they raise must be answered to the satisfaction of the journal, before a final typeset proof is produced.

The final manuscript will be published online here: <http://imr.sagepub.com/content/early/recent>.

Search: keyword,  
Search

 0

---

The list of authors should include all those who can legitimately claim authorship. This is all those who.

1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
2. Drafted the article or revised it critically for important intellectual content,
3. Approved the version to be published,
4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the [International Committee of Medical Journal Editors \(ICMJE\) authorship guidelines](#) for more information on authorship.

Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the [International Committee of Medical Journal Editors \(ICMJE\) authorship guidelines](#) for more information on authorship.

[\[Return to top\]](#)

## 7. Acknowledgements

All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

### 7.1 Writing assistance

Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual's name, company and level of input – and identify the entity that paid for this assistance.

It is not necessary to disclose use of language polishing services.

Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

[\[Return to top\]](#)

## 8. Funding

*Journal of International Medical Research* requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the [Funding Acknowledgements](#) page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

[\[Return to top\]](#)

Search: keyword,  
Search



For guidance on conflict of interest statements, please see the [ICMJE recommendations](#).

[\[Return to top\]](#)

## 10. Research ethics and patient consent

Medical research involving human subjects must be conducted according to the [World Medical Association Declaration of Helsinki](#).

Submitted manuscripts should conform to the [ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals](#), and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

Please also refer to the [ICMJE Recommendations for the Protection of Research Participants](#)

All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the [Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals](#) published by the International Association of Veterinary Editors.

[\[Return to top\]](#)

## 11. Clinical trials

*Journal of International Medical Research* endorses the [ICMJE requirement](#) that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the [AllTrials campaign](#), retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

[\[Return to top\]](#)

## 12. Reporting guidelines

The relevant [EQUATOR Network](#) reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed [CONSORT](#) flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed [PRISMA](#) flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The [EQUATOR wizard](#) can help you identify the appropriate guideline.

Other resources can be found at [NLM's Research Reporting Guidelines and Initiatives](#).

[\[Return to top\]](#)

## 13. Data



Search: keyword,  
Search



maintained website will need to be loaded onto either the journal's platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. [The editor may consider limited embargoes on proprietary data.] The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at [JIMR.editor@sagepub.co.uk](mailto:JIMR.editor@sagepub.co.uk).

[\[Return to top\]](#)

## 14. Publishing policies

### 15. Publication ethics

SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics' [International Standards for Authors](#) and view the Publication Ethics page on the [SAGE Author Gateway](#).

#### 15.1 Plagiarism

*Journal of International Medical Research* and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

#### 15.2 Prior publication

If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the [SAGE Author Gateway](#) or if in doubt, contact the Editor at the address given below.

[\[Return to top\]](#)

### 16. Contributor's publishing agreement

Before publication SAGE requires the author as the rights holder to sign a Journal Contributor's Publishing Agreement. *Journal of International Medical Research* publishes manuscripts under [Creative Commons licenses](#). The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit [SAGE's OA licenses page](#).

Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author's request.

[\[Return to top\]](#)

## 17. Preparing your manuscript



Search: keyword,  
Search

0

Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google.

The abstract should be a summary of no more than 200 words, and should state its purpose, the basic procedure, main findings and principal conclusions. New and important observations or aspects of the study should be emphasised. Summaries for all papers except narrative review articles and case reports should be structured with the following headings: OBJECTIVE, METHODS (include type of study/experimental design and type of participant), RESULTS, CONCLUSIONS. Summaries of narrative review articles and case reports should be a brief overview of the main points.

[\[Return to top\]](#)

## 20. Artwork, figures and other graphics

For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE's [Manuscript Submission Guidelines](#).

Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, please request these when you submit your article to the journal.

Graphs and images that are unsuitable may be returned to the author for amendment, causing delay in publication.

Tables must be prepared in Word using proper table formatting with columns and rows. Tables created using tabs or any other type of formatting may be returned to the author for amendment as they cannot be worked on by the journal, causing delay in publication.

As many tables as necessary may be included as long as there is no repetition of data. For example do not include the same data as both a table and a figure. They should be numbered consecutively using Arabic numbers, e.g. TABLE 2, and they must have a brief caption and be referred to in the main body of the text.

[\[Return to top\]](#)

## 21. Reference style

*Journal of International Medical Research* adheres to the SAGE Vancouver reference style. Please review the [guidelines on SAGE Vancouver](#) to ensure your manuscript conforms to this reference style.

If you use [EndNote](#) to manage references, you can download the [SAGE Vancouver output file here](#).

[\[Return to top\]](#)

## 22. English language editing services

Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal's specifications should consider using SAGE Language Services. Visit [SAGE Language Services](#) on our Journal Author Gateway for further information.

[\[Return to top\]](#)

## 23. Submitting your manuscript

*Journal of International Medical Research* is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit <https://mc.manuscriptcentral.com/jimr> to login and



Search: keyword,  
Search

🛒 0

As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of [ORCID](#), the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.

We encourage all authors to add their ORCID to their SAGE Track accounts and include their ORCID as part of the submission process. If you don't already have one you can create *one* [here](#).

[\[Return to top\]](#)

## 25 Information required for completing your submission

You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

[\[Return to top\]](#)

## 26. Corresponding author contact details

Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

[\[Return to top\]](#)

## 27. Permissions

Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.

[\[Return to top\]](#)

## 28. Technical Edit

Once the paper has been accepted, the page charge fee is payable. Publication in the journal is on a page charge basis, the current rate being 325 GBP (+VAT where applicable) per printed journal page, assuming no colour figures (colour figures are subject to an additional fee). This charge is based on the page count estimate made upon submission.

[\[Return to top\]](#)

## 29. Proofs

Once payment is received, the next phase is an in depth, detailed technical edit by two, sometimes three, medical Technical Editors. The corresponding author will be emailed by a Technical Editor with an accompanying list of queries in a Word document. On average, there are 50-80 queries raised during the technical edit stage. These should be answered clearly and quickly, with the agreement of all co-authors and to the satisfaction of the journal. Following that, a final typeset proof will be produced for final checks before publication. No further charges or refunds will be granted to reconcile any difference between the page charge fee paid for upon acceptance and the final printed page count.



Search: keyword,  
Search



We value your feedback to ensure we continue to improve our author service levels. On publication all corresponding authors will receive a brief survey questionnaire on your experiences of publishing in *Journal of International Medical Research* with SAGE.

[\[Return to top\]](#)

### 31. Online publication

One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

[\[Return to top\]](#)

### 32. Promoting your article

Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the [Promote Your Article](#) page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to [maximise your article's impact with Kudos](#).

[\[Return to top\]](#)

### 33. Further information

Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the *Journal of International Medical Research* editorial office as follows:

[JIMR.admin@sagepub.com](mailto:JIMR.admin@sagepub.com)

[\[Return to top\]](#)

Search on SAGE Journals  
submit

Advertising

Current Issue

Email Alert

Foreign rights

Permissions

Read Online

Reprints and sponsorship

Rate card

Subscribe

Individual Subscription, Print Only



Search: keyword,  
Search

0

---

£139.00

Buy now

---

Institutional Backfile Purchase, E-access (Content through 1998)

£1,982.00

Buy now

---

Institutional, Single Print Issue

£13.00

[Info](#)

---

Individual, Single Print Issue

£15.00

[Info](#)

---

## Browse

Books

Journals

Digital Products

Reference Books

Catalogues

## Resources for

Instructors

Book Authors/Editors

Journal Authors/Editors/Reviewers

Students

Researchers

Librarians

Booksellers



Search: keyword,  
Search

0

- 
- Careers
  - Accessibility
  - Modern Slavery Statement
  - Policies and Statements

Social

[Blog](#)[Facebook](#)[Twitter](#)[LinkedIn](#)[Social Science Space](#)

---

You are in: **Europe**

[Change location](#)